reSee.it Video Transcript AI Summary
The speaker claims that when the rotavirus vaccine was approved, four out of five board members had direct financial interests in it, working for the companies that made the vaccine or receiving grants to do clinical trials on it.
One board member, Paul Offit, allegedly voted to add the rotavirus vaccine to the schedule while he had a rotavirus vaccine in development. The speaker says that because it's now on the schedule, his developing vaccine is virtually guaranteed to get on the schedule.
The rotavirus vaccine that Offit voted on was withdrawn within a year because it was causing intussusception in kids. Offit's vaccine then replaced it. The speaker states that Offit and his business partners sold that vaccine to Merck for $186,000,000. The speaker says that Offit told Newsweek that he won the lottery and that it's been said of him that he voted himself rich.